Aurobindo sells subsidiary in Australia to Eris Pharma

14 April 2015

Indian drugmaker Aurobindo Pharma (BSE: 524804) has sold its step down subsidiary Aurobindo Pharma Australia, with operations in Australia and New Zealand, to privately-held Eris Pharmaceuticals, an Australian pharmaceutical company whose products are sold in the Middle East, North Africa, CIS and Balkans countries.

The subsidiary was not contributing any profit to Aurobindo. Financial terms of the transaction have not been disclosed.

As a result of this acquisition of marketing authorizations for prescription and over-the-counter (OTC) medicines through its ownership of Aurobindo Australia, Eris will become a significant generic pharmaceutical company in Australia. The Eris product portfolio offered to Australian pharmacists includes prescription generics, OTCs, dermo-cosmetic and other healthcare products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK